Compile Data Set for Download or QSAR
Report error Found 44 Enz. Inhib. hit(s) with all data for entry = 1780
TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339899(US9758480, 99 | (3S)-1-[(trans-4-{(1S)-1-[(tert-Bu...)
Affinity DataIC50: 6nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339903(US9758480, 114)
Affinity DataIC50: 7nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339926(US9758480, 212 | Pentyl 5-{[(3S)-1-[(trans-4-{(1S)...)
Affinity DataIC50: 8nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339882(US9758480, 23 | 5-{(2S,3S)-1-[trans-4-(tert-Butoxy...)
Affinity DataIC50: 9nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339927(US9758480, 213 | Cyclopropylmethyl 5-{[(3S)-1-[(tr...)
Affinity DataIC50: 10nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339889(US9758480, 35)
Affinity DataIC50: 14nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339888(US9758480, 34)
Affinity DataIC50: 28nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339925(US9758480, 211 | Tetrahydro-2H-pyran-4-ylmethyl 5-...)
Affinity DataIC50: 29nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339890(US9758480, 38)
Affinity DataIC50: 30nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339920(US9758480, 184 | tert-Butyl [(1S)-1-(trans-4-{[(2S...)
Affinity DataIC50: 30nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339919(US9758480, 178 | Cyclopentylmethyl 5-{[(3S)-1-[(tr...)
Affinity DataIC50: 33nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339896(US9758480, 53 | 5-[(2S,3S)-1-{trans-4-[(1S)-1-(ter...)
Affinity DataIC50: 34nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339884(US9758480, 24 | 5-{(2S,3S)-1-[trans-4-(tert-Butoxy...)
Affinity DataIC50: 34nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339906(US9758480, 121 | (2S)-Tetrahydrofuran-2-ylmethyl 5...)
Affinity DataIC50: 43nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339893(US9758480, 40 | 5-[(2S,3S)-1-{trans-4-[1-(tert-But...)
Affinity DataIC50: 45nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339910(US9758480, 134)
Affinity DataIC50: 54nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339921(US9758480, 186 | tert-Butyl [(1S)-1-(trans-4-{[(2S...)
Affinity DataIC50: 60nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339891(US9758480, 39 | 5-[(2S,3S)-1-{trans-4-[1-(tert-But...)
Affinity DataIC50: 63nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339905(US9758480, 118)
Affinity DataIC50: 65nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339912(US9758480, 138)
Affinity DataIC50: 72nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339917(US9758480, 170)
Affinity DataIC50: 76nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339887(US9758480, 29 | 5-[(2S,3S)-1-{trans-4-[1-(tert-But...)
Affinity DataIC50: 82nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339895(US9758480, 50)
Affinity DataIC50: 84nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339894(US9758480, 46 | 5-[(2S,3R)-1-{trans-4-[1-(tert-But...)
Affinity DataIC50: 90nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339900(US9758480, 102)
Affinity DataIC50: 93nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339898(US9758480, 96)
Affinity DataIC50: 98nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339909(US9758480, 133)
Affinity DataIC50: 99nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339874(US9758480, 5 | 5-{cis-1-[trans-4-(Aminomethyl)cycl...)
Affinity DataIC50: 125nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339876(US9758480, 14 | tert-Butyl trans-4-{cis-2-[3-fluor...)
Affinity DataIC50: 130nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339916(US9758480, 148)
Affinity DataIC50: 140nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339902(US9758480, 113)
Affinity DataIC50: 145nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339908(US9758480, 130 | 4-Methoxybutyl 5-({(3S)-1-[(trans...)
Affinity DataIC50: 195nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339915(US9758480, 147)
Affinity DataIC50: 205nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339897(US9758480, 55)
Affinity DataIC50: 220nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339922(US9758480, 187 | (3S)-1-[(trans-4-{(1S)-1-[(tert-B...)
Affinity DataIC50: 285nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339918(US9758480, 171 | (2S)-2-Methoxypropyl 5-{[(3R)-1-[...)
Affinity DataIC50: 300nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339911(US9758480, 137)
Affinity DataIC50: 380nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339907(US9758480, 122)
Affinity DataIC50: 690nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339914(US9758480, 146)
Affinity DataIC50: 916nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339904(US9758480, 115)
Affinity DataIC50: 1.50E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339901(US9758480, 103)
Affinity DataIC50: 2.35E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339913(US9758480, 141 | 3-Ethoxypropyl 5-({(3R)-1-[(trans...)
Affinity DataIC50: 3.45E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339923(US9758480, 196)
Affinity DataIC50: 3.50E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Sumitomo Dainippon Pharma

US Patent
LigandPNGBDBM339924(US9758480, 201 | 3-(Morpholin-4-yl)propyl 5-{[(3S)...)
Affinity DataIC50: 4.10E+3nMAssay Description:0.35 μg/mL human FXIa was allowed to react with a substrate and a test compound in a 30 mmol/L HEPES buffer solution (pH 7.4) that contained 145...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/22/2019
Entry Details
US Patent